MedPath

Assessment of subconjunctival bevacizumab effect on the postoperative healing course and recurrence of excised pterygium

Not Applicable
Conditions
pterygium.
corneal degeneration
Registration Number
IRCT138805192326N1
Lead Sponsor
Vice-chancellery of Research Affairs of Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
32
Inclusion Criteria

the patients with primary pterygium referring to the ophthalmology clinics, affiliated to Shiraz University of Medical Sciences, that want pterygium removal. Exclusion criteria: glaucoma, regurgitation from lacrimal punctum (any indication of nasolacrimal obstruction), patients that seems not coming for follow-up exams during study, not treated diabetic patients, autoimmune diseases, pregnant patients, patients with ocular surface diseases or infections, two headed pterygium, previous limbal surgery, previous pterygial surgery.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recurrence of pterygium. Timepoint: 1 month, 3 months, 6 months after operation. Method of measurement: Slit lamp examination and measuring the size of recurrent pterygial tissue on cornea.
Secondary Outcome Measures
NameTimeMethod
Healing of the surgical wound. Timepoint: 1 week,1 month. Method of measurement: observing erythema, subconjunctival hemorrhage, corneal epithelial defect, tearing, photophobia of the patients.
© Copyright 2025. All Rights Reserved by MedPath